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for overall mortality after 13 years is 1.01 (95% CI 0.99-
1.03). The best trials failed to show a significant reduction
in breast cancer mortality with a relative risk of 0.97 (95%
CI 0.82-1.14). If data from all eligible trials (excluding
flawed studies) are considered then the relative risk for
breast cancer mortality after 13 years is 0.80 (95% CI
0.71-0.89). However, breast cancer mortality is considered
to be an unreliable outcome and biased in favour of screen-
ing. Flaws are due to differential exclusion of women with
breast cancer from analysis and differential misclassifica-
tion of cause of death.
Reviewer’s conclusions The currently available reliable
evidence does not show a survival benefit of mass screen-
ing for breast cancer (and the evidence is inconclusive for
breast cancer mortality). Women, clinicians and policy
makers should consider these findings carefully when
they decide whether or not to attend or support screening
programs.
The methodologist’s point of view
L. Moja, I. Moschetti, A. Liberati
We selected this review from The Cochrane Library for four
main reasons. First, it addresses an issue of great public
health relevance, which, in many ways, has been often
referred to as ‘a model case’ for an evidence-based assess-
ment of a population intervention. Second, it indicates that
the same ‘evidence base’can be interpreted in different ways
depending on the “quality/methodology filter” adopted.
Third, it shows that the aim of being ‘fully explicit and repro-
ducible’ is not an easy one. Finally, it shows that the rela-
tionship between research evidence and health policy is more
complex than usually anticipated.
A key date to dispute about screening for breast cancer
In 2000 a systematic review by Gotzsche and Olsen pub-
lished in Lancet concluded that ‘Screening for breast cancer
with mammography is unjustified’ [1]. The statement was
sharp, direct and emotional. This was the conclusion of one
of the most controversial reviews developed within The
Cochrane Collaboration.
Looking at outcomes, numbers and trial subgroups
The results in the first Lancet review version reported
that, when only the two trials considered adequately ran-
domised were meta-analysed, the combined relative risk
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Screening for breast cancer with mammography.
Cochrane Database Syst Rev (4):CD001877
Background Mammographic screening for breast cancer
is controversial, as reflected in greatly varying national
policies.
Objectives The objective was to assess the effect of screen-
ing for breast cancer with mammography on mortality and
morbidity.
Search strategy MEDLINE (16 May 2000), The Cochrane
Breast Cancer Group's trial register (24 Jan 2000) and refer-
ence lists. Letters, abstracts and unpublished trials. Authors
were contacted. 
Selection criteria Randomised trials comparing mammo-
graphic screening with no mammographic screening. 
Data collection and analysis Data were extracted by both
authors independently. 
Main results Seven completed and eligible trials involv-
ing half a million women were identified. The two best tri-
als provided medium-quality data and, when combined,
yield a relative risk for overall mortality of 1.00 (95% CI
0.96-1.05) after 13 years. However, the trials are under-
powered for all-cause mortality, and confidence intervals
include a possible worthwhile effect as well as a possible
detrimental effect. If data from all eligible trials (exclud-
ing flawed studies) are considered then the relative risk58 L. Moja et al.: Good and harm from screening studies 
(RR) was 1.04 (95% CI 0.84–1.27), with no effect of
screening on breast cancer-specific mortality. No effect
on total mortality emerged (0.99 (0.94–1.05)), though the
studies were underpowered for this outcome. Gotzsche
and Olsen stressed the point that all-cause (total) mortal-
ity should be preferred to disease-specific as primary out-
come, because it is more reliable. Cancer-specific mor-
tality (i.e., breast cancer deaths) is difficult to assess con-
sistently and tends to favour breast screening. The pooled
RR for breast cancer mortality for the other trials, con-
sidered by the authors to be methodologically flawed,
was 0.75 (0.67–0.83), a result significantly different
(p=0.005) from that for the two unbiased trials. In the
review the authors refused to calculate the total pooled
RR as they felt that the two groups of trials should not be
combined.
The Cochrane–Lancet dispute
A different version of the same review was also published
in the Cochrane Library and presented less negative con-
clusions, claiming that the available evidence was compat-
ible with both a beneficial and detrimental effect of screen-
ing [2]. This was the result of a long and complex peer
review process that took place within the Cochrane Breast
Cancer Review Group, which strongly challenged the con-
clusion, revising it against the authors’ wishes [3]. The
Lancet supported Gotzsche and Olsen’s original view
against screening and stated that the Cochrane editors’
attempt to negotiate the ‘spin’ that authors placed on their
work diminished the value of the Cochrane review [4, 5].
Same methods and results sections, different emphasis in
the authors’ conclusions; different impact on screening
policies. The conflict raised by the interpretation even
eroded the friendship of the investigators themselves.
Olsen, who designed how the trials’ quality was related to
the results, the core of the review, is no longer part of the
authorship.
The complex balance
There are at least two reasons why this controversial
Cochrane review is worth discussing. First, it clarified
that the benefit from breast cancer screening is small.
How small? It corresponds to an absolute risk reduction
in breast cancer mortality of 0.05%: for every 2000
women invited for screening over 10 years (not one), one
will have her life prolonged (only one). The relatively
low numbers of events means that misclassification or
biased exclusion of a few deaths could change the statis-
tical significance of the trial results. More importantly,
they may change the direction. Furthermore, one could
also start looking at harm from screening; in their origi-
nal review Gotzsche and Olsen highlighted anxiety,
labelling effect, false-positive results, unnecessary biop-
sies and the cascade of treatments to treat cancers of
uncertain clinical significance coming from screening.
Ten healthy women will be diagnosed as cancer patients
and will be treated because of false-positive findings.
That the effect of breast cancer screening is modest was
also recognised by another systematic review developed
by the US Preventive Task Force, which hypothesised an
absolute risk reduction of 0.1 [6]. The expectation of
harms is relevant compared with the benefits. Informed
consent for women contemplating whether to attend a
breast screening programme is now a fundamental ele-
ment of good practice: the information should consider
that the possible mortality benefit is counter-balanced by
extra surgical risks, particularly for those women
younger than 50. As this age threshold is somewhat arbi-
trary, all women should be advised about possible risks.
In summary, most of the mammography trials have
methodological limitations. Eliminating the information
coming from these trials completely erases the mortality
benefit. And it is hard to imagine that new randomised
trials will be performed in the future. Keeping this infor-
mation in the meta-analyses gives a small (SMALL)
advantage to screening.
The bottom line
Meta-analyses developed through systematic reviews are
not an atlas that offers readers several equally reliable
routes through the terrain mapped out by the authors.
Rather, meta-analyses depend on the stringency of the
methodological quality assessment filter that is applied.
By examining this quality assessment more closely, we
come to see the authors’intention and the means by which
they convey this intention [7]. Assessing the quality of evi-
dence is a complex task and this assessment should con-
sider not only elements of the study design but also aspects
of study conduct, epidemiological relevance and consis-
tency. All readers should examine the consistency and
transparency of authors’ conclusions against the way they
have set forth the quality filter of their own analysis. In the
end it is this transparency that make systematic reviews
better than opinion-based narrative ones.
The clinician’s point of view
G.F. Gensini, R. Gusinu
Screening for cancer remains a very emotional and debat-
ed issue of great public health relevance in the contempo-
rary medical practice. This review from the CochraneL. Moja et al.: Good and harm from screening studies  59
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Library shows that the analysis of published data results
in multiple opinions based on a limited amount of reli-
able data.
In the same way the relationship between research-based
evidence and health policy is more complex than usually
anticipated and recommendations and decisions regarding
cancer screening should be based on highly reliable data,
and not on assumptions or speculations.
The assessment of the balance between benefits and
disadvantages from screening studies is particularly com-
plex in this specific area due to the importance of the
methodological quality filter applied to the studies.
This systematic review represents an excellent model of
conditions characterised by great public health relevance, by a
number of clinical trials available, but severely affected by the
uneven quality of trials.
This may lead to markedly different conclusions in rela-
tion to the filter applied to the quality of the evidence pro-
duced by trials, stressing the importance of a thorough eval-
uation of the stability and strength of medical evidence, as
very clearly described in a recent paper [8].
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